Abstract
There is a family of proteins - integrins, which are generally expressed at low levels on epithelial cells and mature endothelial cells, but they are highly expressed on the surface of both endothelial cells in tumor neovasculature and some tumor cells, including osteosarcomas, neuroblastomas, glioblastomas, melanomas, and carcinomas of the lung, the breast, the prostate, and the bladder. The alpha(v)beta(3) integrin plays a critical role in angiogenesis and tumor metastasis. Angiogenic blood vessels overexpress alpha(v)beta(3) integrin, as in tumor neovascularization, while alpha(v)beta(3) integrin expression in other microvascular beds and organs is limited. Therefore, alpha(v)beta(3) integrin is a suitable receptor for tumor-targeting therapy and imaging. The alpha(v)beta(3) integrin-targeting properties and the therapeutic potential of various radiolabeled RGD peptides are herein discussed.
Keywords: Integrin, alpha(v)beta(3), RGD peptide, therapy, imaging
Current Radiopharmaceuticals
Title: Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides
Volume: 2 Issue: 3
Author(s): Petar M. Mitrasinovic
Affiliation:
Keywords: Integrin, alpha(v)beta(3), RGD peptide, therapy, imaging
Abstract: There is a family of proteins - integrins, which are generally expressed at low levels on epithelial cells and mature endothelial cells, but they are highly expressed on the surface of both endothelial cells in tumor neovasculature and some tumor cells, including osteosarcomas, neuroblastomas, glioblastomas, melanomas, and carcinomas of the lung, the breast, the prostate, and the bladder. The alpha(v)beta(3) integrin plays a critical role in angiogenesis and tumor metastasis. Angiogenic blood vessels overexpress alpha(v)beta(3) integrin, as in tumor neovascularization, while alpha(v)beta(3) integrin expression in other microvascular beds and organs is limited. Therefore, alpha(v)beta(3) integrin is a suitable receptor for tumor-targeting therapy and imaging. The alpha(v)beta(3) integrin-targeting properties and the therapeutic potential of various radiolabeled RGD peptides are herein discussed.
Export Options
About this article
Cite this article as:
Mitrasinovic M. Petar, Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides, Current Radiopharmaceuticals 2009; 2 (3) . https://dx.doi.org/10.2174/1874471010902030214
DOI https://dx.doi.org/10.2174/1874471010902030214 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Has Selenium a Chemopreventive Effect on Hepatocellular Carcinoma?
Mini-Reviews in Medicinal Chemistry Quantifying Glomerular Filtration Rates: Kidney Function Analysis Method and Apparatus
Recent Patents on Biomarkers Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Sialic Acid Donors: Chemical Synthesis and Glycosylation
Current Organic Synthesis A Search for Inhibitors of S100B, a Member of the S100 Family of Calcium-Binding Proteins
Mini-Reviews in Medicinal Chemistry Recent Advances in the Chemistry and Synthesis of Thienopyrazine, Pyrrolopyrazine and Furopyrazine Derivatives
Current Organic Chemistry Muscarinic Receptors as Targets for Metronomic Therapy in Breast Cancer
Current Pharmaceutical Design Fast and Sensitive Liquid Chromatography Method for Simultaneous Determination of Methylisothiazolinone, Salicylic Acid and Parabens in Cosmetic Products
Current Analytical Chemistry Low Dose Aspirin, COX-Inhibition and Chemoprevention of Colorectal Cancer
Current Topics in Medicinal Chemistry The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Current Signal Transduction Therapy Hypoxic Culture Conditions for Mesenchymal Stromal/Stem Cells from Wharton’s Jelly: A Critical Parameter to Consider in a Therapeutic Context
Current Stem Cell Research & Therapy Branched-Chain Amino Acids and Pigment Epithelium-Derived Factor: Novel Therapeutic Agents for Hepatitis C Virus-Associated Insulin Resistance
Current Medicinal Chemistry Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology A Personalized Approach to Systemic Treatment of Unresectable or Metastatic Pancreatic Adenocarcinoma
Current Pharmacogenomics and Personalized Medicine Edelfosine in Membrane Environment - the Langmuir Monolayer Studies
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease
Current Alzheimer Research A Storage Protein-Like Trypsin Inhibitor from the Moth Bean (Phaseolus acutifolius) with Antiproliferative Activity Toward Lymphoma Cells
Protein & Peptide Letters Bladder Cancer and Stem Cells
Current Signal Transduction Therapy P-glycoprotein Inhibition: The Past, the Present and the Future
Current Drug Metabolism Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials
Current Drug Metabolism